Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

The agritech industry is editing plant genomes to feed a growing population, expand the produce aisle, and make tastier, more convenient food products.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

After two decades of failure, novel scientific insights and technical progress are spurring meaningful innovation in the field.